DEFA14A: atai Life Sciences to Acquire Beckley Psytech, Forming "atai Beckley" as Psychedelic Medicine Leader

atai Life Sciences announced a business combination with Beckley Psytech, aiming to become the leading psychedelic medicine company and will be renamed "atai Beckley" following the closing.

Summary

• atai Life Sciences (Nasdaq: ATAI) is acquiring the remaining approximately two-thirds ownership of Beckley Psytech, following an initial strategic investment in January 2024 that gave atai an approximate one-third stake.
• The acquisition will result in 100% ownership of Beckley Psytech and full internalization of its lead compound, BPL-003, into atai's pipeline.
• Beckley's shareholders (excluding atai) will receive approximately 105 million new atai shares, representing about 31% of the combined company on a fully diluted basis upon closing and concurrent private placement.
• All newly issued shares are subject to a lock-up period.
• BPL-003 is a proprietary, patent-protected intranasal formulation of 5-MeO-DMT, with Phase 2b data anticipated for mid-2025.
• A downside protection mechanism is in place: atai is only required to maintain a recommendation for the acquisition if Phase 2b data for BPL-003 meets pre-defined success criteria.
• The acquisition marks atai's transformation into a fully operational biotech company with 100% ownership of major programs, except for its strategic stake in Compass Pathways (Psilocybin) and the anticipated spin-out of ELE-101 (IV psilocin) from Beckley.
• atai has also acquired minority shares in DemeRx (Ibogaine program to 100% ownership) and IntelGenx (manufacturing, patent enhancement), and advanced its VLS-01 (DMT) and EMP-01 (R-MDMA) programs into Phase 2.
• The company emphasizes a focus on a "2-hour treatment window" for its psychedelic programs, similar to Johnson & Johnson's Spravato, for commercial viability.
• Ferring Ventures SA and Adage Capital Partners LP are expanding their investments in atai, with Adage doubling down.

Sentiment

Score: 9

Explanation: The document conveys extremely positive sentiment regarding the acquisition, strategic positioning, pipeline strength, investor confidence, and future commercial prospects. It frames the transaction as a major milestone and a culmination of strategic efforts to become a 'psychedelic powerhouse.'

Positives

• Strategic acquisition of Beckley Psytech positions atai as a potential leader in the psychedelic medicine field, with a planned renaming to "atai Beckley."
• Internalization of BPL-003 (5-MeO-DMT) into atai's pipeline, a compound considered a "strongest psychedelic" with promising Phase 2b data anticipated mid-2025, showing rapid, durable antidepressive effects (up to three months) and short treatment times (less than two hours).
• The acquisition completes atai's transformation into a fully operational biotech company with 100% ownership of most major programs, enhancing control and potential profitability.
• Downside protection negotiated for BPL-003 Phase 2b data, mitigating risk for atai if results do not meet expectations.
• Strong intellectual property and patent portfolio development across atai's programs, aimed at protecting future commercial success.
• Focus on "2-hour treatment window" for psychedelic therapies, aligning with the commercially successful model of Johnson & Johnson's Spravato, which is projected to generate several billion in revenues by 2026.
• Strategic investments from Ferring Ventures SA and Adage Capital Partners LP, indicating strong institutional confidence in atai and the combined entity.
• Increased political and regulatory support for psychedelic therapy, with the new FDA Commissioner Marty Makari calling psychedelic medicines a "top priority" and mentioning compounds like Psilocybin, MDMA, and Ibogaine (all covered by atai).
• The co-founder's personal commitment, having only bought atai shares and agreeing to a 12-month voluntary lockup, mirroring new shares issued to Beckley shareholders.

Negatives

• The success of the acquisition and the combined entity heavily relies on the positive outcome of BPL-003 Phase 2b data, which is still anticipated.
• The "downside protection" implies a potential scenario where the Phase 2b data for BPL-003 might not meet atai's expectations, which could impact the acquisition's perceived value.
• The biotech sector has experienced negativity over the past 2-3 years, which could continue to be a headwind for atai despite its strategic moves.
• The 105 million new atai shares issued to Beckley shareholders, equating to approximately 31% of the combined company, represents significant dilution for existing atai shareholders.

Risks

• Clinical Trial Risk: Actual results of clinical trials, including Beckley's BPL-003 Phase 2b trial and atai's other programs (VLS-01, EMP-01, RL-007), could differ materially from projections.
• Regulatory Approval Risk: The potential, success, cost, and timing of development and regulatory approval of product candidates are uncertain.
• Integration Risk: Risks associated with the closing of the transaction, including timing and approvals, and the integration of Beckley Psytech's operations into atai.
• Financial Synergies Risk: Expectations regarding financial synergies from the combined company may not be realized.
• Market Acceptance Risk: Despite the focus on a 2-hour treatment window, market acceptance and commercial viability of psychedelic treatments are not guaranteed.
• Intellectual Property Risk: While atai prioritizes IP, the ability to protect the fruits of its labor through patents and IP portfolios is subject to legal challenges and competition.
• Competition: The psychedelic medicine space is evolving, and competition from other companies developing similar treatments could impact atai's market position.
• Forward-Looking Statements Disclaimer: The document explicitly states that forward-looking statements involve known and unknown risks and uncertainties that could cause actual results to differ materially.

Future Outlook

atai anticipates becoming the "undoubted leader" in psychedelic medicine, to be renamed "atai Beckley," and aims to bring all medically viable psychedelics under one roof. The company expects significant commercial success by focusing on a "2-hour treatment window" for its therapies, similar to the successful Spravato model, and by leveraging its strong intellectual property portfolio. Key clinical data readouts for BPL-003 and RL-007 are expected in mid-2025, which are critical milestones for the company's pipeline. The company also hints at future announcements regarding its non-hallucinogenic neuroplasticity enhancers.

Management Comments

• "Today marks a very proud and emotional milestone: atai Life Sciences (Nasdaq: ATAI), the psychedelics medicine company I co-founded 2018, announced a business combination with Beckley Psytech, positioning atai to be renamed into 'atai Beckley'to be the undoubted leader in the field."
• "Amanda was very supportive in these discussions, even while battling cancer, and it is an immense honor to continue her legacy together with her son Cosmo in working to bring all the psychedelics she loved so much back into the world as regulated pharmaceuticals."
• "What has not changed despite this transformation is my vision and aspiration for atai: to create THE psychedelic powerhouse, getting all medically viable psychedelics under one roof. And (IMHO) we succeeded. Big time."
• "Psychedelics have demonstrated remarkable potential as a transformative class of treatments for a range of mental health conditions. atai has consistently led innovation and progress in this space, and I am pleased to expand our investment to support the company in pioneering the next generation of mental health treatments." Jean-Frederic Paulsen, Chairman Ferring Ventures SA
• "I couldn't wish for a better strategic pharma investor, and I am sure their experience, network and support will be very beneficial to atai."
• "Investing in atai without any conditionality on closing of the acquisition suggests to me that Adage has confidence both in atai, and in the potential of the combined entity."
• "This slow start is still on the mind of many investors, who predict a similar slow roll out for Compass and atai. They couldn't be more wrong, imo."
• "Mental health is IMO the defining medical challenge of our time. And I believe that addressing it with transformative psychedelic treatments will not only impact patients in need but also (if and as successfully developed and commercialized) provide great returns for shareholders."

Industry Context

The announcement comes amidst a "psychedelic renaissance" and strong political support for psychedelic therapy, with the new FDA Commissioner Marty Makari designating psychedelic medicines as a "top priority." The industry is learning from the commercialization of Johnson & Johnson's Spravato, which, despite a slow start, became a blockbuster drug by leveraging a 2-hour treatment window and educating therapists and patients. atai's strategy of focusing on shorter treatment durations (2 hours for DMT/5-MeO-DMT) aims to capitalize on established infrastructure and processes in clinics that are already familiar with the "Spravato Window," potentially giving it a commercial advantage over therapies requiring longer in-clinic times like Psilocybin (6 hours) or LSD (12 hours).

Comparison to Industry Standards

• atai's focus on a "2-hour treatment window" for its lead psychedelic programs (DMT, 5-MeO-DMT) directly compares to Johnson & Johnson's Spravato (Esketamine), which also requires a 2-hour in-clinic treatment and has become a blockbuster drug projected to make several billion in revenues by 2026. This aligns atai with a proven commercially viable model.
• In contrast, Psilocybin, which atai covers indirectly via its stake in Compass Pathways, typically involves a 6-hour treatment duration, and LSD can be 12 hours. The document suggests these longer durations will likely be "harder to establish" commercially compared to the 2-hour window.
• The document highlights that while the general public lamented the "Lykos failure" (likely referring to a setback in MDMA development by another company), atai drove its own EMP-01 (R-MDMA) program into Phase 2, indicating continued progress in a challenging segment.
• The acquisition of IntelGenx for manufacturing and patent enhancement suggests a move towards vertical integration and IP protection, a common strategy among leading biopharma companies to secure market position.

Stakeholder Impact

• Shareholders: Existing atai shareholders will experience dilution due to the issuance of 105 million new shares (approx. 31% of combined company) to Beckley shareholders. However, the acquisition is presented as enhancing long-term value and positioning atai for significant returns.
• Patients: The acquisition aims to accelerate the development and availability of transformative psychedelic treatments for mental health conditions, potentially offering more convenient (2-hour) treatment options.
• Therapists/Healthcare Providers: The focus on a 2-hour treatment window aligns with existing infrastructure and processes established by Spravato, potentially easing adoption and integration of new psychedelic therapies.
• Employees: The combined entity, "atai Beckley," will likely involve integration of teams and operations, potentially impacting employees of both companies.

Next Steps

• Closing of the business combination between atai Life Sciences and Beckley Psytech, subject to certain closing conditions.
• Renaming of atai Life Sciences to "atai Beckley" following the closing.
• Release of Phase 2b data for BPL-003 (5-MeO-DMT) anticipated for mid-2025.
• Release of Phase 2b proof-of-concept trial data for RL-007 (for CIAS) anticipated for mid-2025.
• Further development and potential commercialization of atai's product candidates, including non-hallucinogenic neuroplasticity enhancers.
• Filing of a proxy statement on Schedule 14A and other relevant documents with the SEC regarding the proposed transaction.

Key Dates

Recommendation

Keywords

atai Life Sciences, Beckley Psytech, psychedelic medicine, BPL-003, 5-MeO-DMT, mental health, clinical trials, biotech, acquisition, merger, drug development, neuroscience, depression, intellectual property, FDA, Spravato, Psilocybin, Ibogaine, DMT, R-MDMA, CIAS, neuroplasticity